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Pharmacokinetics Of Linezolid 
During Extracorporeal Membrane Oxygenation 
 
Sir, 
The extracorporeal membrane oxygenation (ECMO) is increasingly used in the 
critical setting for patients with respiratory failure and there is a growing body of 
knowledge describing the associated  variations in plasma concentrations of drugs, 
including antibiotics, due to drug adsorption on the different components of the 
ECMO circuit. Currently, a multicentre study is ongoing to confirm if the standard 
antibiotic dosing in adult patients may still be considered appropriate [1]. Linezolid 
(LNZ) is extensively used in patients with pneumonia in critical care because of its 
strong activity against Staphylococcus aureus and its high pulmonary penetration, 
but there are no data on LNZ pharmacokinetics during ECMO [2]. Here we report the 
main pharmacokinetic parameters in three critically ill patients on ECMO treated with 
LNZ. 
 
Patient 1 was a 61-year-old man, with a body mass index (BMI) of 24, who 
underwent lung transplantation because of chronic obstructive pulmonary disease 
and was treated with LNZ for pneumonia caused by meticillin-resistant S. aureus 
(MRSA) with a LNZ minimum inhibitory concentration (MIC) of 1 mg/L. Patient 2 was 
a 40-year-old woman (BMI = 18) with cystic fibrosis (CF) who was on the transplant 
list, empirically treated with LNZ and previously colonised by MRSA. Patient 3 was a 
32-year-old woman (BMI = 31) with severe pneumonia caused by influenza H1N1 
and pulmonary bacterial superinfection by meticillin-susceptible S. aureus (LNZ MIC 
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= 4 mg/L) isolated from bronchoalveolar lavage, previously treated with oxacillin that 
was stopped because of jaundice. 
 
Plasmatic concentrations of LNZ were studied during ECMO, after informed consent 
was signed, at steady-state with the standard dosage of 600 mg every 12 h 
intravenously by 1-h infusion. The area under the curve (AUC) of daily (AUC0–24)   
plasma concentrations of LNZ was calculated with blood samples collected before 
(time 0) and 1, 2.5, 4, 6 and 8 h after the intravenous administration. Minimum 
plasma concentration (Cmin ) is defined as the concentration before the 
administration and the maximum plasma concentration (Cmax ) is defined as the 
concentration at the end of the infusion. LNZ was determined in plasma by ultra 
performance liquid chromatography-photodiode array (UPLC-PDA) method. 
Pharmacokinetic data were studied using Kinetica software (Thermo Scientific, 
Waltham, MA) and AUC0–24 was calculated as AUC0–24 = 2  AUC0–12 [3]. In Table 1 
the main LNZ pharmacokinetic parameters are reported, such as Cmax, Cmin, AUC0–
24, half-life (t1/2), clearance (CL), time above the MIC (t  > MIC) and volume of 
distribution (Vd); we also reported in Table 1 the LNZ pharmacokinetic parameters 
calculated with S. aureus MICs corresponding to 1, 2 and 4 mg/L for Patients 1, 2 
and 3, respectively.  
 
These results show that the calculated pharmacokinetic parameters of LNZ during 
ECMO are satisfactory when the MRSA MIC is ≤1 mg/L, with AUC0-24/MIC ratio 80 
in all patients [3, 4]. Only patient 3 did not display a full 24-hour plasma 
concentration above the MIC = 1 mg/L, with t  > MIC corresponding to 66% of the 
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dosing interval. The rate of achievement of pharmacological parameters decreases 
for all patients with MIC values > 1 mg/L, as detailed in Table 1, for both AUC0-24/MIC 
ratios and t > MIC.  
This is the first report of LNZ plasma concentrations in patients treated with ECMO, 
where we also included calculated data for different MICs to provide a reference for 
future patients. According to our data, even if limited, pharmacokinetic targets are 
not achieved with standard dosage of LNZ when the MRSA MIC is >1 mg/L.  
Notwithstanding the limited sample size and heterogeneity of patients, including lung 
transplant, CF and high BMI, we conclude that plasma pharmacodynamic targets are 
easily achieved only when the S. aureus MIC is ≤1 mg/L. According to our results, 
patients infected by S. aureus with MICs > 1 mg/L on ECMO should be considered, 
pending future confirmation, at considerable risk of inadequate pharmacokinetic 
coverage. Prolonged or continuous infusion of LNZ might be needed in critically ill 
patients to increase AUC0-24/MIC ratios or t > MIC, as well as increased dosage or 
combination therapy. 
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Table 1.  
Pharmacokinetic parameters of linezolid for patients 1, 2 and 3, and calculated data 
for Staphylococcus aureus minimum inhibitory concentrations (MICs) of 1, 2 and 4 
mg/L. 
 Patient 1 Patient 2 Patient 3 
Pharmacokinetic parameters 
Cmax (mg/L) 15.67 18.51 15.61 
Cmin (mg/L) 4.25 0.47 0.43 
AUC0–24 (mg h/L) 212.58 165.65 100.59 
CL (L/h) 5.65 7.24 13.35 
Vd (L) 49.7 17.6 46.77 
t1/2 (h) 6.10 1.68 2.20 
Calculated data 
AUC0–24 /MIC (MIC = 1) 212.58 165.65 100.58 
AUC0–24 /MIC (MIC = 2) 106.29 82.83 50.30 
AUC0–24 /MIC (MIC = 4) 53.14 41.41 25.15 
t>MIC (MIC = 1) (% over 12 h) 100 100 66 
t>MIC (MIC = 2) (% over 12 h) 100 75 41 
t>MIC (MIC = 4) (% over 12 h) 100 58.3 30 
Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; AUC0–
24: area under the curve of plasma daily concentrations; CL, clearance; Vd, volume of 
distribution; t1/2, half-life; t>MIC, time of plasma concentrations above the MIC. 
 
